Overall verdict
Buy
6.6/10
1-year performance
+23.81%
Score breakdown
Up 23.8% over 1 year, 95% of the 52-week range.
Strongest: Profitability 8.8/10. Weakest: Valuation 4.1/10.
5 analysts, target +0.1% vs the price.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Kevin McNamara
Founded
1970
Employees
15 811
Revenue / employee
160 014 USD
Next earnings
February 24, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC3.09%
- Bank of New York Mellon Corp0.70%
- FMR LLC0.23%
- Rest of the register95.99%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
562.24 USD
52-week low
365.20 USD
1-year performance
23.81%
Rising
Year-to-date performance
29.03%
Rising
Drawdown
-1.86%
Near its high
Position in the 52-week range
95% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Chemed | $318,049 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-49 % between May 2007 and April 2008. $10,000 placed at the top fell to $5,090. The world ETF, at worst: -53 %. Back to its high in 36 months.
Chemed earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Chemed: $318,049
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 485.88 USD - 492.88 USD (2 methods agree)
The price implies growth of 7.55% per year; the company grows at -1.20%.
Gross margin 31.0%, net margin 10.6%, ROIC 23.6%, ROE 29.1%.
Net margin
10.61%
Exceptional
Sector 4.51%|S&P 13.40%
Gross margin
31.00%
Fair
Return on equity (ROE)
29.14%
Exceptional
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
23.65%
Exceptional
Free cash flow margin (FCF)
11.10%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.05x
Fair
Margin stability
2.6 pts
Steady
Revenue to net income
Growth
4.5/10Revenue up 10.6% over 1 year, 4.0% a year over 5, EPS -1.2% a year over 5.
Revenue (trailing 12 months)
2.7Md USD
Revenue growth (1y)
10.57%
Solid
Revenue growth (3y)
18.50%
Solid
EPS growth (1y)
22.35%
Solid
EPS CAGR (5y)
-1.20%
Declining
EPS revisions (3 months)
2.16%
Revised up
Valuation
4.1/10P/E 26.4x, forward P/E 24.8x, EV/EBITDA 16.3x, PEG 2.50. The multiple sits in the 52th percentile of its own 5-year history.
P/E (TTM)
26.4x
Fair
Sector 27.8x|S&P 23.6x
Forward P/E
24.8x
Fair
EV / EBITDA
16.3x
Expensive
Sector 12.5x|S&P 15.5x
PEG
2.50
Very expensive
Sector 1.51|S&P 0.91
Fair value (reverse DCF)
489.38 USD
Overvalued
P/E vs its own 5-year history
among the 48% highest valuations
In line with its history
Market cap
7.2Md USD
Financial strength
8.4/10Cash covers 11.8% of the debt, net debt/EBITDA 0.2x.
Net debt / EBITDA
0.2x
Very solid
Gearing (net debt / equity)
41.97%
Solid
Cash
48.4M USD
Cash / market cap
0.67%
Stretched
Cash / total debt
11.81%
Stretched
Interest coverage
75.4x
Very solid
Net debt
362M USD
Equity
861M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 544.49 USD
- MM20525.53
- MM50515.38
- MM200465.84
- RSI 1459.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.88%
200-day average slope, 3 months
+5.83%
50-day average slope, 1 month
-1.06%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.80 % per day
Volatility change
+28.37%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 22.27 (3) | 25.78 (5) | 2 734 (5) | 518 (5) | 296 (4) |
| 2027 | 26.13 (3) | 27.85 (5) | 2 915 (5) | 555 (5) | 338 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 28, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CHE | 6.6 | 6.3 | 7.2Md USD | 26.4x | 10.6 % | 10.6 % | 23.6 % | 0.2x | 4.1 % | 23.8 % | ||
| 2 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 3 | CVS | 6.5 | 6.0 | 115Md USD | 10.4x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.6 % | 14.8 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
